Loading...

SRPT SAREPTA THERAPEUTICS INC Capital Structure Changes 8-K Filing

SRPT

SRPT

SAREPTA THERAPEUTICS INC

(SRPT)

2025 8-K

Show Summary

Summary

Debt Exchange Agreement

Management Change

Clinical Trials

Reduction in Force

Rights Offerings

Earnings Announcement

Credit Agreement

Financial Results

Collaboration Agreement

Amendment to Incentive Plan

Financial Results

FDA Approval of ELEVIDYS

Annual Meeting Results

External Links:

On August 20, 2025, Sarepta Therapeutics, Inc. agreed to exchange $700 million of existing convertible notes for new notes worth $602 million and shares, in addition to $123.3 million in cash.

AI Assistant

SAREPTA THERAPEUTICS INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.